<DOC>
	<DOCNO>NCT00125684</DOCNO>
	<brief_summary>Patients participate two arm trial , one morphine administer transdermally , , 3 day wash period , one morphine administer subcutaneously .</brief_summary>
	<brief_title>Bioavailability Effectiveness Transdermally Administered Morphine</brief_title>
	<detailed_description>Patients participate two arm trial , one morphine administer transdermally , , 3 day wash period , one morphine administer subcutaneously . Blood draw do dose method order compare blood level morphine different route .</detailed_description>
	<mesh_term>Morphine</mesh_term>
	<criteria>Chronic cancer pain Minimum baseline pain 3/10 No change medication 3 day prior study period Ability give inform consent Willingness undergo repeat blood sampling Use morphine codeine 3 day prior study Known sensitivity morphine Prior anaphylactic reaction opioid Clinically significant anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>transdermal morphine</keyword>
	<keyword>cancer</keyword>
	<keyword>pain</keyword>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>cancer relate pain</keyword>
	<keyword>stable baseline pain</keyword>
	<keyword>currently take opioids</keyword>
</DOC>